A retrospective analysis of over 57,000 patients with stage II to III esophageal cancer revealed that both perioperative chemotherapy and trimodality therapy significantly enhance overall survival compared to definitive chemoradiation therapy (DCRT). Perioperative chemotherapy showed a median overall survival of 66.2 months, while trimodality therapy had a median of 43.9 months. In contrast, patients receiving radiotherapy alone faced the worst outcomes, with a median survival of just 13.5 months, highlighting substantial differences in treatment effectiveness.
Journal Article by Jeon WJ, Park D (…) Castillo D et 5 al. in JAMA Netw Open